# Pharmaceuticals - I V Fluids — company-by-company sector analysis

> Pharmaceuticals - I V Fluids: Venus Remedies Ltd owns the largest revenue base AND the fastest current growth.

Sector Alpha — machine-written from the numbers. Data as of 2026-08-20. Not investment advice.

## Bottom line

Pharmaceuticals - I V Fluids has outperformed NIFTY 500 by 269% over 52 weeks and 87.6% over 13 weeks. 1 of 1 covered companies beat NIFTY on Mansfield relative strength, while 0 of 1 beat the sector itself. Venus Remedies Ltd leads with revenue of ₹811 crore, based on 1 of 1 comparable companies through Jun 2026.

## Sector relative strength

Pharmaceuticals - I V Fluids has outperformed NIFTY 500 by 269% over the last 52 weeks. Over 13 weeks the gap is a lead of 87.6%. 1 of 1 covered company currently beats NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Venus Remedies Ltd is the strongest against the sector itself at 0%.

13-week sector return versus NIFTY 500: 88%
52-week sector return versus NIFTY 500: 269%
Stocks leading NIFTY: 1/1
Stocks leading sector: 0/1

Central tension: The central tension: current leadership is concentrated, so durability matters more than rank.

Companies: 1
Combined market value: ₹2.4K Cr

## 4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

1. Venus Remedies Ltd (VENUSREM): 79/100 — Favorable setup; evidence 97%
   - Growth & earnings 34.5/35 | Capital efficiency 20.1/25 | Valuation 12.0/20 | Relative strength 12.5/20
   - Price stage: LEADER — Ahead of the benchmark 13 weeks or more running, and ahead over the past year.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 12 of the last 12 weeks
   - Exact sum: 34.5 + 20.1 + 12 + 12.5 = 79.1
   - Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.

## Market action

Venus Remedies Ltd has the strongest one-year price move in Pharmaceuticals - I V Fluids at +271%. It also leads on Mansfield relative strength against NIFTY at +86.5%. 1 of 1 covered company is above zero on that measure. Every line covers 313 weekly closes through 2026-08-14.

### Strongest one-year price performers
1. Venus Remedies Ltd (VENUSREM): 271%

### Strongest relative strength versus NIFTY 500
1. Venus Remedies Ltd (VENUSREM): 87%

## Pharmaceuticals - I V Fluids — the story behind the numbers

This is the written read behind the Pharmaceuticals - I V Fluids figures above — what is actually happening in the sector, in words, with the evidence each claim rests on. It is dated 28 Jul 2026. 3 themes are live here.

The Pharmaceuticals - I V Fluids sector analysis for the week ending 2026-07-19 focuses on VENUSREM. The company reported consolidated revenue of ₹259.40 crore for Q4 FY26, marking a 31.24% increase year-on-year and 43.9% quarter-on-quarter. Consolidated net profit surged 126.19% YoY to ₹47.50 crore.

How old this read is: This read comes from our Pharmaceuticals - I V Fluids sector brief dated 28 Jul 2026, so the words here and the numbers above them cover the same few weeks.

### Live themes, worst first
- MEDIUM | Export-driven business faces FX volatility from raw material imports and shipping delays that could impact margin consistency. | quoted: "Export-driven business faces FX volatility from raw material imports and shipping delays that could impact margin consistency." | named for VENUSREM
- MEDIUM | Stock under Long Term ASM Stage IV surveillance by BSE as of July 2026, indicating exchange monitoring due to price volatility and trading patterns. | quoted: "Stock under Long Term ASM Stage IV surveillance by BSE as of July 2026, indicating exchange monitoring due to price volatility and trading patterns." | named for VENUSREM
- LOW | Injectable pharmaceuticals business exhibits significant quarterly volatility due to lumpy order fulfillment and customer ordering patterns. | quoted: "Injectable pharmaceuticals business exhibits significant quarterly volatility due to lumpy order fulfillment and customer ordering patterns." | named for VENUSREM

Sources: our Pharmaceuticals - I V Fluids sector brief, 28 Jul 2026 · company earnings-call transcripts.

## Revenue Scale & Growth Durability

What the numbers say: Venus Remedies Ltd is the scale leader at ₹811 crore, Venus Remedies Ltd's growth is 19.4% from a ₹811 crore base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

Investor read: Venus Remedies Ltd is the scale benchmark; Venus Remedies Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Venus Remedies Ltd's growth falls below Venus Remedies Ltd's for two consecutive comparable reports while operating margin also compresses.

Evidence: Venus Remedies Ltd · ₹811 crore | Not enough peers | 7/8 recent comparable periods | 1/1 companies · 20 observations

Definition: Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

### Revenue — largest
1. Venus Remedies Ltd (VENUSREM): ₹811 Cr

### Revenue growth — fastest growers
1. Venus Remedies Ltd (VENUSREM): 19%

### 20-quarter Revenue history
- VENUSREM: Sep 2021 ₹205 Cr | Dec 2021 ₹126 Cr | Mar 2022 ₹137 Cr | Jun 2022 ₹143 Cr | Sep 2022 ₹140 Cr | Dec 2022 ₹117 Cr | Mar 2023 ₹156 Cr | Jun 2023 ₹95 Cr | Sep 2023 ₹168 Cr | Dec 2023 ₹143 Cr | Mar 2024 ₹195 Cr | Jun 2024 ₹109 Cr | Sep 2024 ₹170 Cr | Dec 2024 ₹177 Cr | Mar 2025 ₹195 Cr | Jun 2025 ₹137 Cr | Sep 2025 ₹193 Cr | Dec 2025 ₹180 Cr | Mar 2026 ₹259 Cr | Jun 2026 ₹179 Cr

### 20-quarter Revenue growth history
- VENUSREM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 -32% | Dec 2022 -7.1% | Mar 2023 14% | Jun 2023 -34% | Sep 2023 20% | Dec 2023 22% | Mar 2024 25% | Jun 2024 15% | Sep 2024 1.2% | Dec 2024 24% | Mar 2025 0.0% | Jun 2025 26% | Sep 2025 14% | Dec 2025 1.7% | Mar 2026 33% | Jun 2026 31%

## Operating Economics & Margin Trend

What the numbers say: Venus Remedies Ltd leads both opm at 19% and margin change at +8 percentage points.

Investor read: Venus Remedies Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Evidence: Venus Remedies Ltd · 19% | Not enough peers | 7/8 recent comparable periods | 1/1 companies · 20 observations

Definition: Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

### OPM — highest
1. Venus Remedies Ltd (VENUSREM): 19%

### Margin change — fastest expanders
1. Venus Remedies Ltd (VENUSREM): +8.0 pp

### 20-quarter OPM history
- VENUSREM: Sep 2021 13% | Dec 2021 10% | Mar 2022 3.9% | Jun 2022 10% | Sep 2022 9.3% | Dec 2022 7.0% | Mar 2023 16% | Jun 2023 11% | Sep 2023 11% | Dec 2023 8.0% | Mar 2024 10% | Jun 2024 10% | Sep 2024 4.5% | Dec 2024 10% | Mar 2025 15% | Jun 2025 11% | Sep 2025 16% | Dec 2025 21% | Mar 2026 24% | Jun 2026 19%

### 20-quarter Margin change history
- VENUSREM: Sep 2021 +5.0 pp | Dec 2021 −4.8 pp | Mar 2022 −0.1 pp | Jun 2022 −2.8 pp | Sep 2022 −4.2 pp | Dec 2022 −3.0 pp | Mar 2023 +12.1 pp | Jun 2023 +0.9 pp | Sep 2023 +1.7 pp | Dec 2023 +1.0 pp | Mar 2024 −6.0 pp | Jun 2024 −1.0 pp | Sep 2024 −6.5 pp | Dec 2024 +2.0 pp | Mar 2025 +5.0 pp | Jun 2025 +1.0 pp | Sep 2025 +11.5 pp | Dec 2025 +11.0 pp | Mar 2026 +9.0 pp | Jun 2026 +8.0 pp

## Profit Scale & Acceleration

What the numbers say: Venus Remedies Ltd leads with ₹117 crore of TTM profit, Venus Remedies Ltd shows ≥100% on the scoring scale (112.7% uncapped) growth from a ₹117 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

Investor read: Venus Remedies Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Evidence: Venus Remedies Ltd · ₹117 crore | Not enough peers | 7/8 recent comparable periods | 1/1 companies · 20 observations

Definition: Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

### Net profit — largest
1. Venus Remedies Ltd (VENUSREM): ₹117 Cr

### Profit growth — fastest growers
1. Venus Remedies Ltd (VENUSREM): 100%

### 20-quarter Net profit history
- VENUSREM: Sep 2021 ₹23 Cr | Dec 2021 ₹6 Cr | Mar 2022 ₹0 Cr | Jun 2022 ₹7 Cr | Sep 2022 ₹5 Cr | Dec 2022 ₹3 Cr | Mar 2023 ₹11 Cr | Jun 2023 ₹1 Cr | Sep 2023 ₹10 Cr | Dec 2023 ₹7 Cr | Mar 2024 ₹11 Cr | Jun 2024 ₹1 Cr | Sep 2024 ₹4 Cr | Dec 2024 ₹20 Cr | Mar 2025 ₹21 Cr | Jun 2025 ₹10 Cr | Sep 2025 ₹20 Cr | Dec 2025 ₹26 Cr | Mar 2026 ₹48 Cr | Jun 2026 ₹23 Cr

### 20-quarter Profit growth history
- VENUSREM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 -78% | Dec 2022 -50% | Mar 2023 — | Jun 2023 -86% | Sep 2023 100% | Dec 2023 133% | Mar 2024 0.0% | Jun 2024 0.0% | Sep 2024 -60% | Dec 2024 186% | Mar 2025 91% | Jun 2025 900% | Sep 2025 400% | Dec 2025 30% | Mar 2026 129% | Jun 2026 130%

## Return On Capital Employed

What the numbers say: Venus Remedies Ltd leads ROCE at 21.7%. Venus Remedies Ltd has the strongest latest improvement at +9.9 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

Investor read: Venus Remedies Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

Evidence: Venus Remedies Ltd · 21.7% | Not enough peers | 7/8 recent comparable periods | 1/1 companies · 16 observations

Definition: ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

### ROCE — highest
1. Venus Remedies Ltd (VENUSREM): 22%

### ROCE change — fastest improvers
1. Venus Remedies Ltd (VENUSREM): +9.9 pp

### 20-quarter ROCE history
- VENUSREM: Sep 2021 4.7% | Dec 2021 — | Mar 2022 6.0% | Jun 2022 — | Sep 2022 1.6% | Dec 2022 — | Mar 2023 5.4% | Jun 2023 — | Sep 2023 6.0% | Dec 2023 9.1% | Mar 2024 6.1% | Jun 2024 8.6% | Sep 2024 4.2% | Dec 2024 11% | Mar 2025 8.6% | Jun 2025 14% | Sep 2025 12% | Dec 2025 17% | Mar 2026 17% | Jun 2026 24%

### 20-quarter ROCE change history
- VENUSREM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 −3.1 pp | Dec 2022 — | Mar 2023 −0.6 pp | Jun 2023 — | Sep 2023 +4.4 pp | Dec 2023 — | Mar 2024 +0.7 pp | Jun 2024 — | Sep 2024 −1.8 pp | Dec 2024 +1.6 pp | Mar 2025 +2.5 pp | Jun 2025 +5.2 pp | Sep 2025 +7.8 pp | Dec 2025 +6.7 pp | Mar 2026 +8.2 pp | Jun 2026 +9.9 pp

## Valuation Against Growth & Quality

What the numbers say: Venus Remedies Ltd has the lowest comparable PEG at 0.46×. Only 1 of 1 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

Evidence: Venus Remedies Ltd · 0.46× | Not enough peers | 0/8 recent comparable periods | 1/1 companies · 6 observations

Definition: PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

### PEG — lowest PEG
1. Venus Remedies Ltd (VENUSREM): 0.5

### P/E — lowest P/E
1. Venus Remedies Ltd (VENUSREM): 20.5

### 20-quarter PEG history
- VENUSREM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 0.4 | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 2.1 | Mar 2024 — | Jun 2024 2.3 | Sep 2024 0.3 | Dec 2024 1.7 | Mar 2025 — | Jun 2025 0.5 | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —

### 20-quarter P/E history
- VENUSREM: Sep 2021 14.4 | Dec 2021 9.2 | Mar 2022 6.9 | Jun 2022 6.6 | Sep 2022 7.6 | Dec 2022 13.4 | Mar 2023 13.8 | Jun 2023 12.8 | Sep 2023 16.2 | Dec 2023 21.3 | Mar 2024 15.0 | Jun 2024 16.8 | Sep 2024 15.8 | Dec 2024 18.6 | Mar 2025 14.4 | Jun 2025 16.0 | Sep 2025 12.6 | Dec 2025 16.6 | Mar 2026 15.1 | Jun 2026 25.3


## What can make this comparison misleading?
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.

## Every company
- Venus Remedies Ltd (VENUSREM) — market value ₹2.4K Cr; latest fundamentals Jun 2026

## Source standing of each company

Cross-checked: 1. Unverified: 0. Withheld: 0. Graded companies: 1.

Every company's second-feed figures reconcile against the primary source on overlapping reported periods, so nothing here is unverified or withheld.

## Methodology and freshness

Fundamentals through Jun 2026; prices through 2026-08-14.
Up to 20 quarters per company. Reported history is normalized to Indian rupees crore. Missing values are not interpolated. Derived metrics are calculated only when their inputs are comparable.

## Frequently asked questions

### Is the Pharmaceuticals - I V Fluids sector outperforming NIFTY 500?

Pharmaceuticals - I V Fluids has outperformed NIFTY 500 by 269% over 52 weeks and 87.6% over 13 weeks. 1 of 1 covered companies beat NIFTY on Mansfield relative strength, while 0 of 1 beat the sector itself.

### Which Pharmaceuticals - I V Fluids company is largest by revenue?

Venus Remedies Ltd leads with revenue of ₹811 crore, based on 1 of 1 comparable companies through Jun 2026.

### Which Pharmaceuticals - I V Fluids company is growing fastest?

Venus Remedies Ltd has the fastest current revenue growth at 19.4%, across 1 of 1 comparable companies.

### Which Pharmaceuticals - I V Fluids company has the strongest 4-Factor Sector Score?

Venus Remedies Ltd ranks first at 79.1/100 with 97% evidence confidence. The score prioritizes research; it is not a buy recommendation.

### Which Pharmaceuticals - I V Fluids company has the lowest comparable PEG?

Venus Remedies Ltd has the lowest comparable PEG at 0.46, among 1 of 1 companies whose earnings and growth are steady enough for the ratio to mean anything.

### How much history does this Pharmaceuticals - I V Fluids comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

### How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

### Is there a Nifty Pharmaceuticals - I V Fluids index?

NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Pharmaceuticals - I V Fluids, this page builds its own equal-weight basket of 1 listed Pharmaceuticals - I V Fluids companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.

### Which are the best Pharmaceuticals - I V Fluids stocks in India?

Ranked by this page's four-factor score, Venus Remedies Ltd places first among 1 listed Pharmaceuticals - I V Fluids companies. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

### How many Pharmaceuticals - I V Fluids stocks are listed in India?

This comparison covers 1 listed Pharmaceuticals - I V Fluids companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.

### Which Pharmaceuticals - I V Fluids company is the biggest?

Venus Remedies Ltd is the largest, with trailing-twelve-month revenue of ₹811 crore. That covers 1 of 1 companies with comparable reporting through Jun 2026.

### Which Pharmaceuticals - I V Fluids company has the best profit margins?

Venus Remedies Ltd has the highest operating margin at 19%, from 1 of 1 comparable companies. Venus Remedies Ltd shows the biggest recent improvement, at +8 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

### Which Pharmaceuticals - I V Fluids company makes the most profit?

Venus Remedies Ltd earns the most, at ₹117 crore of trailing-twelve-month net profit, from 1 of 1 comparable companies. Venus Remedies Ltd has the fastest profit growth at the ≥100% scoring cap, though growth off a small or recovering profit base overstates how much has actually changed.

### Which Pharmaceuticals - I V Fluids company earns the highest return on capital?

Venus Remedies Ltd leads on return on capital employed at 21.7%, across 1 of 1 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

### Which Pharmaceuticals - I V Fluids stock is the cheapest?

On PEG — where a LOWER number is cheaper — Venus Remedies Ltd screens cheapest at 0.46×. All 1 companies qualify for the ratio comparison. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

### Is the Pharmaceuticals - I V Fluids sector beating the market?

Pharmaceuticals - I V Fluids has outperformed NIFTY 500 by 269% over the last 52 weeks and 87.6% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 1 of 1 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

### Which Pharmaceuticals - I V Fluids stock has the strongest price momentum?

Venus Remedies Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

### Which Pharmaceuticals - I V Fluids company scores highest for research priority?

Venus Remedies Ltd scores 79.1 out of 100 with 97% evidence confidence, from 34.5 points on growth and earnings, 20.1 on capital efficiency, 12 on valuation and 12.5 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

### How many Pharmaceuticals - I V Fluids companies does this comparison cover, and over what period?

It compares 1 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

### What is the total market cap of the Pharmaceuticals - I V Fluids sector?

The 1 Pharmaceuticals - I V Fluids companies on this page carry ₹2,382 crore of combined market value. Venus Remedies Ltd is the largest at ₹2,382 crore, about 100% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-20.

### How is the Pharmaceuticals - I V Fluids sector performing?

1 of the 1 covered Pharmaceuticals - I V Fluids companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 269% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-20.

### Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

### Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.